Direct Reprogramming of Liver Progenitor Cells for Dual Differentiation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for producing hepatocytes from non-hepatic cells result in cells with poor proliferation potency and inability to differentiate into cholangiocytes.

Innovation Solution

An in vitro method involving the introduction of specific combinations of reprogramming factors, such as HNF1, HNF6, and FOXA, or their gene counterparts, into non-hepatic stem or progenitor cells, including vascular endothelial cells, to induce hepatic stem or progenitor cells capable of differentiating into hepatocytes and cholangiocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional reprogramming factors (CEBPA, HNF4A, FOXA3, GATA4, HNF1A) are introduced into human fibroblasts to produce hepatocytes, then hepatocyte differentiation is achieved, but proliferation potency is poor

Engineering Contradiction:
Improvehepatocyte differentiation capabilityVSAvoidproliferation potency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent changes the parameters of reprogramming by selecting a completely different factor combination (HNF1A, HNF6, FOXA3, and optionally L-MYC) from conventional factors. This parameter change in the reprogramming cocktail enables the resulting hepatocytes to maintain both differentiation capability and proliferation potency, resolving the contradiction between reliable hepatocyte production and productive proliferation.

Inventive Principle:
Principle #35Parameter changes

2Manufacturing precision

If conventional reprogramming methods are used to induce hepatocytes from non-hepatic cells, then hepatocyte phenotype is achieved, but differentiation into cholangiocytes is impossible

Engineering Contradiction:
Improvehepatocyte phenotype accuracyVSAvoiddifferentiation potential into cholangiocytes
Core Design Contradiction:
Manufacturing precisionVSAdaptability or versatility

Solution Approach 1:

The patent applies universality by designing a reprogramming system that produces hepatocytes with multi-functional differentiation potential. The use of HNF1A, HNF6, and FOXA3 creates hepatocytes that not only maintain authentic hepatocyte phenotype but also retain the versatility to differentiate into cholangiocytes, thereby resolving the contradiction between manufacturing precision and adaptability.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentEP3702449B1Method for producing liver stem cells or liver progenitor cells by direct reprogramming
Publication Date: 2026.04.15 KYUSHU UNIV
  • EP3702449B1 patent drawingFigure 1A~1D
  • EP3702449B1 patent drawingFigure 2A~2B
  • EP3702449B1 patent drawingFigure 3A~3D

AI summary

A method for inducing conversion from non-hepatic stem cells or non-hepatic progenitor cells into hepatic stem cells or hepatic progenitor cells, which comprises introducing any of the following combinations into the non-hepatic stem cells or non-hepatic progenitor cells: (a) a combination of HNF1, HNF6 and FOXA; (b) a combination of HNF1 gene, HNF6 gene and FOXA gene; (c) a combination of HNF1, MYC and FOXA; or (d) a combination of HNF1 gene, MYC gene and FOXA gene.